Acute Kidney Injury After Surgical AVR and Long-Term Risk of Death and End-Stage Renal Disease  by Rydén, Linda C. et al.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 6 , N O . 2 0 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C .LettersAcute Kidney Injury After
Surgical AVR and
Long-Term Risk of Death
and End-Stage Renal
DiseaseSeveral studies have reported the incidence and prog-
nosis related to acute kidney injury (AKI) after trans-
catheter aortic valve replacement (1). We performed a
nationwide cohort study to investigate the incidence
of AKI and its relation to mortality and end-stage renal
disease (ESRD) in patients who underwent isolated
surgical aortic valve replacement (SAVR).
We identiﬁed all patients who underwent a pri-
mary isolated SAVR between 1999 and 2013 from the
SWEDEHEART registry. We excluded patients with
kidney transplants or on dialysis. AKI was deﬁned
according to Kidney Disease Improving Global Out-
comes criteria: stage 1 as a $0.3 mg/dl ($26 mmol/l) or
a 1.5- to 1.9-fold increase; stage 2 as a 2.0- to 2.9-fold
increase; and stage 3 as a $3.0-fold increase in post-
operative serum creatinine levels, a serum creati-
nine level of $4.0 mg/dl ($354 mmol/l), or initiation of
renal replacement therapy. Linkage with nationalTABLE 1 Event Rates and Relative Risk for All-Cause Mortality and E
Aortic Valve Replacement According to AKI Stage
No AKI*
Death
Events/person-yrs 1,606/44,080
Incidence rate (per 1,000 person-yrs) 36 (35–38)
Crude HR (95% CI) 1.00
Age- and eGFR-adjusted HR (95% CI) 1.00
Multivariable-adjusted HR† (95% CI) 1.00
End-stage renal disease
Events/person-yrs 10/49,002
Incidence rate (per 1,000 person-yrs) 0.2 (0.1–0.4)
Crude sHR (95% CI) 1.00
Age- and eGFR-adjusted sHR (95% CI) 1.00
*Reference category. †Model included age, sex, region of birth, education, civil status,
vascular disease, prior percutaneous coronary intervention, prior myocardial infarction, le
dependency, emergent operation, and endocarditis.
AKI ¼ acute kidney injury; CI ¼ conﬁdence interval; eGFR ¼ estimated glomerular ﬁlthealth data registries provided vital status and
comorbidities. ESRD was deﬁned as initiation of di-
alysis or kidney transplantation, and was retrieved
from the Swedish Renal Registry. Cox regression was
used to estimate hazard ratios and 95% conﬁdence
intervals for all-cause mortality according to AKI
stage. Age was modeled by restricted cubic splines,
and all other variables were included as categorical
terms. Competing risk regression was used to esti-
mate subdistribution hazard ratios and 95% conﬁ-
dence intervals for ESRD, using death as a competing
event. Statistical analyses were performed using Stata
version 13.1 (StataCorp, College Station, Texas). The
regional ethics committee approved the study.
In total, 9,047 patients were included, and 1,523
(17%) patients developed AKI. Patients with AKI were
older and had more comorbidities than patients
without AKI. During a mean follow-up of 5.6  3.7
years, 2,109 (23%) patients died and 29 (0.3%) pa-
tients developed ESRD (Table 1). Long-term mortality
was almost doubled in stage 1 and increased more
than 3-fold in stages 2 to 3 AKI. The adjusted
relative risk for death was increased by 27% among
patients in stage 1 AKI and more than doubled in
AKI stages 2 to 3 (Table 1). The incidence and the
relative risk of ESRD increased with advancing AKI
stage. We found no evidence of effect modiﬁcationnd-Stage Renal Disease in Patients Who Underwent
AKI Stage
Stage 1 Stages 2 and 3
368/5,678 135/1,160
65 (59–72) 116 (98–138)
1.96 (1.74–2.21) 3.66 (3.04–4.40)
1.47 (1.30–1.66) 2.78 (2.30–3.37)
1.27 (1.12–1.44) 2.47 (2.03–3.00)
11/7,068 8/1,779
1.6 (0.9–2.8) 4.5 (2.2–9.0)
7.6 (3.3–18.0) 21.0 (8.5–53.0)
4.4 (1.7–12.0) 5.3 (1.6–18.0)
body mass index, eGFR, diabetes mellitus, hypertension, hyperlipidemia, peripheral
ft ventricular ejection fraction, heart failure, stroke, atrial ﬁbrillation, cancer, alcohol
ration rate; HR ¼ hazard ratio; sHR ¼ subdistribution hazard ratio.
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2264by age, sex, renal function, left ventricular ejection
fraction, diabetes, or peripheral vascular disease.
In a nationwide cohort of 9,047 patients in Sweden
who underwent isolated SAVR over a 15-year period,
we found that a small increase in post-operative serum
creatinine of only $0.3 mg/dl ($26 mmol/l) was asso-
ciated with a 27% increased risk of death and a >4-fold
increased risk of ESRD during follow-up. The
increased risk of death or ESRD in patients with AKI
was independent of pre-operative renal function and
other clinically relevant parameters. The main
strength of our study was the nationwide population-
based design with complete and accurate follow-up,
ensuring a high external validity. The main limita-
tions were that few patients developed ESRD during
follow-up, which resulted in low precision in ESRD
risk estimates and the possibility of residual con-
founding. Our ﬁndings are interesting, because very
few patients had established coronary artery disease
and because risk factors for cardiovascular disease
were less prevalent than in previous studies on AKI
after cardiac surgery that included patients who had
coronary artery disease. In the present study, the as-
sociations between AKI and increased risk of ESRD
were similar to the results of our prior study on AKI
after coronary artery bypass graft (CABG) and risk of
ESRD (2). Patients who underwent isolated CABG were
more often diabetic (23% vs. 14%) and more likely to
have had a prior myocardial infarction (45% vs. 8%)
compared with patients in the present study (2).
These ﬁndings strengthen the idea that there
may well be a causal relationship between AKI and
adverse outcomes and that AKI may not merely be a
marker of more advanced atherosclerotic disease.
From a clinical perspective, we believe that our
ﬁndings underscore the need for close monitoring
of patients with AKI. This may be especially
important for patients who undergo isolated SAVR
because they are less likely to receive medication
that can prevent deterioration of renal function
compared with CABG patients, who often already
have guideline-recommended secondary prevention
medication.Linda C. Rydén, MD, PhD
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BMI Reduction Decreases
AF Recurrence Rate in a
Mediterranean CohortThe interesting reading of the excellent articles by
Pathak et al. (1,2) triggered us to retrospectively re-
view a cohort of 1,068 consecutive patients with
atrial ﬁbrillation (AF), to evaluate whether the cor-
relation between body mass index (BMI) and AF
behavior could also be veriﬁed in an unselected
group of Mediterranean patients, being that, to the
best of our knowledge, such information is still
unreported.
Among 653 patients referred between 2005 and
2014, 258 patients with the following data available
were included: electrocardiographic (ECG) docu-
mentation of paroxysmal or persistent AF, initial
and follow-up BMI data, reliable ability to report
AF-related symptoms, exhaustive clinical history,
guidelines-consistent (3) treatment, and at least
3 reassessments during a minimum 6-months
follow-up period. Exclusion criteria were the same
as in LEGACY (Long-Term Effect of Goal Directed
Weight Management on Atrial Fibrillation Cohort: A
5 Year Follow-Up Study). According to BMI and its
variation during follow-up, patients were stratiﬁed
into 4 groups, as follows: Group 1 (n ¼ 42, baseline
BMI <25 kg/m2 and unchanged during the follow-
up); Group 2 (n ¼ 81, BMI >25 kg/m2 and losing 2 or
more units during the follow-up); Group 3 (n ¼ 73,
with BMI >25 kg/m2, unchanged during the follow-
up); Group 4 (n ¼ 62, BMI >25 kg/m2 and gaining
2 or more units during the follow-up). All were
encouraged to keep/reach BMI #25 kg/m2 with diet
and/or moderate exercise. Overall follow-up was
602 patient-years. ECG-documented AF recurrences
were most frequent in Group 4 patients, with a
signiﬁcant correlation between BMI behavior and
